Manal F. Abdelmalek, MD

Professor of Medicine
Campus mail 03119 Hosp South, Suite 03107, Room 03125, Durham, NC 27710
Phone (919) 684-3262
Email address manal.abdelmalek@duke.edu

My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.

In Their Words

Education and Training

  • Fellow in Gastroenterology, Medicine, Mayo School of Health Sciences, 1995 - 1998
  • Medical Resident, Medicine, Mayo School of Health Sciences, 1992 - 1995
  • M.D., University Missouri Kansas City, 1992

Publications

Garcia-Tsao, Guadalupe, Jaime Bosch, Zeid Kayali, Stephen A. Harrison, Manal F. Abdelmalek, Eric Lawitz, Sanjaya K. Satapathy, et al. “Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.” J Hepatol 72, no. 5 (May 2020): 885–95. https://doi.org/10.1016/j.jhep.2019.12.010.

PMID
31870950
Full Text

Eslam, Mohammed, Arun J. Sanyal, Jacob George, and Jacob International Consensus Panel. “MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.” Gastroenterology 158, no. 7 (May 2020): 1999-2014.e1. https://doi.org/10.1053/j.gastro.2019.11.312.

PMID
32044314
Full Text

Glass, Oliver, Claudia Filozof, Mazen Noureddin, Mark Berner-Hansen, Elmer Schabel, Stephanie O. Omokaro, Jörn M. Schattenberg, et al. “Standardization of Diet and Exercise in Clinical Trials of NAFLD-NASH: Recommendations from the Liver Forum.” J Hepatol, April 27, 2020. https://doi.org/10.1016/j.jhep.2020.04.030.

PMID
32353483
Full Text

Chalasani, Naga, Manal F. Abdelmalek, Guadalupe Garcia-Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary Rinella, Mazen Noureddin, et al. “Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.” Gastroenterology 158, no. 5 (April 2020): 1334-1345.e5. https://doi.org/10.1053/j.gastro.2019.11.296.

PMID
31812510
Full Text

Liu, Xue-Jing, Li Xie, Kuo Du, Chang Liu, Ning-Ping Zhang, Chen-Jian Gu, Ying Wang, et al. “Succinate-GPR-91 receptor signalling is responsible for nonalcoholic steatohepatitis-associated fibrosis: Effects of DHA supplementation.” Liver Int 40, no. 4 (April 2020): 830–43. https://doi.org/10.1111/liv.14370.

PMID
31903720
Full Text

Ratziu, Vlad, Arun Sanyal, Stephen A. Harrison, Vincent Wai-Sun Wong, Sven Francque, Zachary Goodman, Guruprasad P. Aithal, et al. “Cenicriviroc Treatment for Adults with Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study.” In Hepatology, 2020. https://doi.org/10.1002/hep.31108.

PMID
31943293
Full Text

Satapathy, Sanjaya K., Yu Jiang, Uchenna Agbim, Cen Wu, David E. Bernstein, Lewis W. Teperman, Satish K. Kedia, et al. “Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox.” In Liver Transpl, 26:68–79, 2020. https://doi.org/10.1002/lt.25672.

PMID
31665561
Full Text

Siddiqui, Mohammad Shadab, Mark L. Van Natta, Margery A. Connelly, Raj Vuppalanchi, Brent A. Neuschwander-Tetri, James Tonascia, Cynthia Guy, et al. “Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.” J Hepatol 72, no. 1 (January 2020): 25–33. https://doi.org/10.1016/j.jhep.2019.10.006.

PMID
31634532
Full Text

Du, Kuo, Satish K. Chitneni, Ayako Suzuki, Ying Wang, Ricardo Henao, Jeongeun Hyun, Richard T. Premont, et al. “Increased Glutaminolysis Marks Active Scarring in Nonalcoholic Steatohepatitis Progression.” Cell Mol Gastroenterol Hepatol, December 25, 2019. https://doi.org/10.1016/j.jcmgh.2019.12.006.

PMID
31881361
Full Text

Anstee, Quentin M., Brent A. Neuschwander-Tetri, Vincent Wai-Sun Wong, Manal F. Abdelmalek, Zobair M. Younossi, Jiacheng Yuan, Maria Lucia Pecoraro, et al. “Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design.” Contemp Clin Trials 89 (December 24, 2019): 105922. https://doi.org/10.1016/j.cct.2019.105922.

PMID
31881392
Full Text

Pages